GlassScriptPhysician profile
Dewey J Bailey
NPI 1285628446
$645,254.63
in general payments reported to CMS, 2019-2025
61 companies · $57K in 2025
The $57K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176K · 2020: $83K · 2021: $111K · 2022: $112K · 2023: $46K · 2024: $61K · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $133K · Food and Beverage: $14K · Travel and Lodging: $8,457 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,375 · Honoraria: $2,763 · Consulting Fee: $1,200 · Education: $45.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $133,497.44 |
| Food and Beverage | $14,474.55 |
| Travel and Lodging | $8,457.19 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,375.00 |
| Honoraria | $2,762.50 |
| Consulting Fee | $1,200.00 |
| Education | $45.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $266,168.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $121,000.86 | 2019-2025 | Evenity, Repatha, Tepezza |
| Astrazeneca Pharmaceuticals LP | $71,023.15 | 2019-2024 | Farxiga, Lokelma |
| Lilly USA, LLC | $39,885.80 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $25,106.54 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Janssen Pharmaceuticals, INC | $25,080.15 | 2019-2020 | |
| Mannkind Corporation | $24,327.40 | 2019-2025 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24,009.52 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $15,956.17 | 2022-2025 | |
| Esperion Therapeutics, INC. | $9,071.31 | 2021-2022 | |
| Shire North American Group INC | $6,869.71 | 2019 | |
| Xeris Pharmaceuticals, INC. | $4,904.46 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $1,553.33 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $1,499.47 | 2019-2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $709.70 | 2019-2025 | Tymlos |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $683.23 | 2019-2025 | Ubrelvy |
| Antares Pharma, INC. | $608.15 | 2019-2023 | Xyosted, Tlando, Nocdurna |
| Corcept Therapeutics | $587.89 | 2019-2025 | Korlym |
| Ibsa Pharma INC. | $539.20 | 2020-2025 | Tirosint, Tirosint, Licart |
| Amarin Pharma, INC. | $517.83 | 2019-2023 | |
| Horizon Therapeutics Plc | $486.02 | 2019-2023 | Tepezza |
| Medtronic, INC. | $465.12 | 2022-2025 | Minimed 780g |
| Insulet Corporation | $453.81 | 2019-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $380.05 | 2019-2025 | |
| Recordati_rare_diseases_inc. | $332.58 | 2020-2025 | Isturisa, Signifor Lar |
| Eisai INC. | $284.66 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $258.03 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $206.13 | 2021-2023 | Unithroid |
| Nevro Corp. | $201.10 | 2022-2024 | Senza |
| Alexion Pharmaceuticals, INC. | $184.86 | 2022-2025 | Strensiq |
| Ascendis Pharma Endocrinology INC | $155.27 | 2023-2025 | Yorvipath |
| Merck Sharp & Dohme LLC | $154.00 | 2019-2022 | |
| Acella Pharmaceuticals, LLC | $136.73 | 2022-2025 | NP Thyroid 60 |
| Tersera Therapeutics LLC | $126.90 | 2022-2023 | Xermelo |
| Pfizer INC. | $117.79 | 2019-2025 | |
| Sequel Med Tech, LLC | $96.80 | 2025 | Twiist |
| Medtronic Minimed, INC. | $92.67 | 2019-2020 | |
| Beta Bionics, INC. | $86.83 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Nestle Healthcare Nutrition INC. | $79.00 | 2021 | |
| Halozyme INC | $76.20 | 2023 | |
| Grt US Holding, INC. | $72.51 | 2022 | |
| Gilead Sciences, INC. | $69.92 | 2019 | |
| Eusa Pharma (US) LLC | $65.34 | 2022 | |
| Kyowa Kirin, INC. | $58.34 | 2024-2025 | Crysvita |
| Verity Pharmaceuticals INC. | $52.16 | 2024 | Tlando |
| Astellas Pharma US INC | $46.30 | 2023-2024 | Veozah |
| Ionis Pharmaceuticals, INC. | $46.23 | 2025 | Tryngolza |
| Ultragenyx Pharmaceutical INC. | $45.59 | 2021-2024 | Crysvita, Crysvita |
| Neurocrine Biosciences, INC. | $43.13 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $35.24 | 2019 | |
| Vifor Pharma, INC. | $32.41 | 2020 | |
| Ascensia Diabetes Care US INC. | $31.02 | 2025 | |
| Currax Pharmaceuticals LLC | $27.71 | 2020-2021 | |
| Madrigal Pharmaceuticals | $27.57 | 2025 | Rezdiffra |
| Clarus Therapeutics INC. | $22.07 | 2021 | |
| Embecta Corp. | $21.14 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Becton, Dickinson and Company | $18.86 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $17.56 | 2025 | Imcivree |
| Rgh Enterprises LLC | $16.98 | 2025 | |
| Chiesi USA, INC. | $16.59 | 2025 | Myalept |
| Endo Pharmaceuticals INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dewey Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.